X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration will assist Biological E in both manufacturing and commercializing Qdenga (live attenuated tetravalent dengue vaccine). This vaccine is intended for the treatment of individuals afflicted with Dengue fever.
Lead Product(s): Live Attenuated Tetravalent Dengue Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Qdenga
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 26, 2024
Details:
Corbevax (covid-19 vaccine) is a protein subunit vaccine containing receptor binding domain (RBD) of SARS-CoV-2 virus. It has received WHO emergency use listing approval.
Lead Product(s): Covid-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Corbevax
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
An intramuscular formulation of a 14-valent pneumococcal conjugate vaccine, for the prevention of pneumococcal disease, including childhood pneumonia, meningitis, ear infections and bacteraemia infection caused by Streptococcus pneumoniae.
Lead Product(s): 14-valent Pneumococcal Conjugate Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: PCV14
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022
Details:
India's first indigenously developed RBD protein subunit vaccine Corbevax (BECOV2D) is currently being used to inoculate children in the age group of 12 to 14 years under the COVID-19 immunisation programme.
Lead Product(s): BECOV2D
Therapeutic Area: Infections and Infectious Diseases Product Name: Corbevax
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022
Details:
CorbeVax COVID-19 Vaccine (BECOV2D) based on classical protein subunit vaccine technology of protein antigen in combination with another approved adjuvant, uses harmless piece of spike protein stimulate and prepare human immune system for future with beta coronavirus.
Lead Product(s): BECOV2D
Therapeutic Area: Infections and Infectious Diseases Product Name: Corbevax
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2022
Details:
CorbeVax® COVID-19 Vaccine (BioE COVID-19, BECOV2D) is based on classical a protein subunit vaccine technology of a protein antigen, SARS-CoV-2 Spike receptor-binding domain (RBD), adsorbed to the adjuvant Alhydrogel (Alum), in combination with another approved adjuvant.
Lead Product(s): BECOV2D
Therapeutic Area: Infections and Infectious Diseases Product Name: Corbevax
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022
Details:
CORBEVAX is a “recombinant protein sub-unit” vaccine, developed from a component of the spike protein on the virus’s surface, which helps the body build the immune response against the virus.
Lead Product(s): BECOV2D
Therapeutic Area: Infections and Infectious Diseases Product Name: Corbevax
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Details:
The emergency use approval for restricted use in the 12-18 age group for Corbevax is based on the results of an ongoing mid- to late-stage clinical study, Biological E. The company's shot, Corbevax, is the third vaccine approved for use in children aged 12 and above in India.
Lead Product(s): BECOV2D
Therapeutic Area: Infections and Infectious Diseases Product Name: Corbevax
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2022
Details:
Corbevax is in phase-3 trials and likely to complete all the studies by end of November which is when company is expecting licence. The licence for children should follow one month later.
Lead Product(s): BECOV2D
Therapeutic Area: Infections and Infectious Diseases Product Name: Corbevax
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
Details:
Corbevax is an RBD protein based sub-unit vaccine against the coronavirus infections. Corbevax is based on a protein antigen technology that binds to the Angiotensin Converting Enzyme-2 (ACE2) receptor on the host cell membrane.
Lead Product(s): BECOV2D
Therapeutic Area: Infections and Infectious Diseases Product Name: Corbevax
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
